<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02353832</url>
  </required_header>
  <id_info>
    <org_study_id>STU 092013-013</org_study_id>
    <nct_id>NCT02353832</nct_id>
  </id_info>
  <brief_title>Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer</brief_title>
  <official_title>Phase II Study of Stereotactic Ablative Radiotherapy (SABR) for Low Risk Prostate Cancer With Injectable Rectal Spacer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Texas Southwestern Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Texas Southwestern Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose is to determine if use of rectal spacers are effective at improving protection of
      rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of
      acute effects. It is also to determine whether it provides sufficient dosimetric benefits to
      warrant further clinical investigation in future SABR (Stereotactic Ablative Body Radiation)
      related clinical studies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A phase II study to assess safety and efficacy of the spacer injection process, ability of
      the spacer to effectively provide the space necessary to reduce acute events in the rectum,
      and also meet the SABR based rectal constraints, and to monitor stability of this process
      during SABR. Unlike IMRT, which uses smaller dose/fraction, when using such high
      dose/fraction, even a few mm of shift in spacer positioning may impact the dose that the
      rectum receives, and therefore, a rigorous study of stability of material during the SABR
      treatments will need to be determined. If there is some shift, by doing this study, we may be
      able to determine the margin of error that will be necessary in considering rectal organ
      dosimetry, based on the possible shift in positiong that may occur with the spacer over time.

      As the SABR therapy is strictly local, we will select for patients with prostate cancer
      locally confined to the prostate gland. As such, we will select eligibility criteria of low
      risk patients to minimize risk of extraprostatic spread, seminal vesicle invasion, and nodal
      spread. Hormonal therapy may also be used to shrink prostates that are massively enlarged as
      this may also help further reduce length of rectum that will be irradiated. As the primary
      toxicity will likely be mucosal damage, we will avoid enrolling patients with pre-existing
      mucosal dysfunction (including those with previous radiation, TURP, very large prostate
      glands, inflammatory bowel disease) and immunosuppressed individuals based on our phase I
      experience[13]. In this way, patients will be uniformly selected in a fashion that would
      identify patients likely to receive benefit from the therapy.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">November 6, 2014</start_date>
  <completion_date type="Anticipated">December 18, 2022</completion_date>
  <primary_completion_date type="Actual">June 5, 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of Participants With Reduction in Acute Per-prostatic Rectal Ulcer Events Events From 90%+ to &lt;70% (Particularly in the Anterior Rectum)</measure>
    <time_frame>Median 9 months within the end of radiation treatment</time_frame>
    <description>The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Effectiveness of Space Creation of &gt;= 7.5 mm in Protecting Rectum From Toxicity</measure>
    <time_frame>Median 9 months within the end of radiation treatment</time_frame>
    <description>The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Spacer Related Acute Toxicity</measure>
    <time_frame>5 years</time_frame>
    <description>Assess for spacer related acute toxicity. Spacer related toxicity could be related to the procedure itself (bleeding, infection, pain), or secondary effects of spacer (erectile dysfunction, persistent pain and discomfort).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Spacer Stability by Dimensions</measure>
    <time_frame>1 month</time_frame>
    <description>Determine spacer's stability during course of therapy and to ensure that it is stable enough to reliably use for high dose SABR treatments (using cone beam CTs done during each treatments to measure spacer dimensions).</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">44</enrollment>
  <condition>Prostate Cancer</condition>
  <arm_group>
    <arm_group_label>No Arm</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent)</intervention_name>
    <description>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product</description>
    <arm_group_label>No Arm</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  All patients must be willing and capable to provide informed consent to participate in
             the protocol.

          -  Eligible patients must have appropriate staging studies identifying them as AJCC stage
             T1 (a, b, or c) or T2a or T2b adenocarcinoma of the prostate gland. The patient should
             not have direct evidence of regional or distant metastases after appropriate staging
             studies. Histologic confirmation of cancer will be required by biopsy performed within
             180 days of registration.

          -  The patient's Zubrod performance status must be 0-2.

          -  The Gleason score should be less than or equal to 6 or 3+4 if &lt; 50% of a 12 core
             biopsy was involved.

          -  The serum PSA should be less than or equal to 10 ng/ml.

          -  Study entry PSA must not be obtained during the following time frames: 10 day period
             following prostate biopsy; following initiation of ADT; within 30 days after
             discontinuation of finasteride; or within 90 days after discontinuation of
             dutasteride.

          -  Age ≥ 18 years.

          -  Patients may have used prior hormonal therapy, but it should be limited to no more
             than 9 months of therapy prior to enrollment.

          -  The ultrasound, or CT based volume estimation of the patient's prostate gland should
             be ≤ 60 grams.

        Exclusion Criteria:

          -  Subjects who have had previous pelvic radiotherapy or have had chemotherapy or surgery
             for prostate cancer.

          -  Subjects who have plans to receive other concomitant or post treatment adjuvant
             antineoplastic therapy while on this protocol including surgery, cryotherapy,
             conventionally fractionated radiotherapy, hormonal therapy, or chemotherapy given as
             part of the treatment of prostate cancer.

          -  Subjects who have undergone previous transurethral resection of the prostate (TURP) or
             cryotherapy to the prostate. Subjects who have significant urinary obstructive
             symptoms; AUA score must be ≤15 (alpha blockers allowed).

          -  Subjects who have a history of significant psychiatric illness.

          -  Men of reproductive potential who do not agree that they or their partner will use an
             effective contraceptive method such as condom/diaphragm and spermacidal foam,
             intrauterine device (IUD), or prescription birth control pills.

          -  Prior invasive malignancy (except non-melanomatous skin cancer) unless disease free
             for a minimum of 3 years (e.g., carcinoma in situ of the breast, oral cavity, or
             cervix are all permissible).

          -  Severe, active co-morbidity, defined as follows:

               -  Unstable angina and/or congestive heart failure requiring hospitalization within
                  the last 6 months.

               -  Transmural myocardial infarction within the last 6 months.

               -  Acute bacterial or fungal infection requiring intravenous antibiotics at the time
                  of registration.

               -  Chronic Obstructive Pulmonary Disease exacerbation or other respiratory illness
                  requiring hospitalization or precluding study therapy within 30 days before
                  registration.

               -  Hepatic insufficiency resulting in clinical jaundice and/or coagulation defects;
                  note, however, that laboratory tests for liver function and coagulation
                  parameters are not required for entry into this protocol.

               -  Acquired Immune Deficiency Syndrome (AIDS) based upon current CDC definition;
                  note, however, that HIV testing is not required for entry into this protocol. The
                  need to exclude patients with AIDS from this protocol is necessary because the
                  treatments involved in this protocol may be significantly immunosuppressive.
                  Protocol-specific requirements may also exclude immuno-compromised patients.

               -  Patients with history of inflammatory colitis (including Crohn's Disease and
                  Ulcerative colitis) are not eligible.

          -  Subjects with a known allergy to polyethylene glycol hydrogel (spacer material) or
             contraindication to spacer products (Duraseal or SpaceOAR).

          -  Subjects with evidence of extraprostatic extension (T3a) or seminal vesicle
             involvement (T3b) on clinical evaluation.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male only study</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>99 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael Folkert, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>UT Southwestern Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Micheal Zelefsky, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Centre</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Southwestern Medical Center</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75390</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>January 16, 2015</study_first_submitted>
  <study_first_submitted_qc>January 28, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 3, 2015</study_first_posted>
  <results_first_submitted>January 18, 2019</results_first_submitted>
  <results_first_submitted_qc>April 16, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">May 7, 2019</results_first_posted>
  <last_update_submitted>March 5, 2020</last_update_submitted>
  <last_update_submitted_qc>March 5, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 23, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Single Arm: Injectable Rectal Spacer</title>
          <description>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent): Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="44"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Single Arm: Injectable Rectal Spacer</title>
          <description>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent): Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="44"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="27"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>YEARS</units>
          <param>Mean</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="70" lower_limit="50" upper_limit="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <description>Male only study</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Participants With Reduction in Acute Per-prostatic Rectal Ulcer Events Events From 90%+ to &lt;70% (Particularly in the Anterior Rectum)</title>
        <description>The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects</description>
        <time_frame>Median 9 months within the end of radiation treatment</time_frame>
        <population>Observed ulceration rate</population>
        <group_list>
          <group group_id="O1">
            <title>Single Arm: Injectable Rectal Spacer</title>
            <description>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent): Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product)</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Participants With Reduction in Acute Per-prostatic Rectal Ulcer Events Events From 90%+ to &lt;70% (Particularly in the Anterior Rectum)</title>
          <description>The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects</description>
          <population>Observed ulceration rate</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Effectiveness of Space Creation of &gt;= 7.5 mm in Protecting Rectum From Toxicity</title>
        <description>The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects</description>
        <time_frame>Median 9 months within the end of radiation treatment</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Single Arm: Injectable Rectal Spacer</title>
            <description>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent): Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product)</description>
          </group>
        </group_list>
        <measure>
          <title>Effectiveness of Space Creation of &gt;= 7.5 mm in Protecting Rectum From Toxicity</title>
          <description>The effectiveness of rectal spacer use was measured to determine if they are effective at improving protection of rectum from high dose radiation, using rate of rectal ulceration as a surrogate measure of acute effects</description>
          <units>mm</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="44"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="11.5" lower_limit="6.6" upper_limit="21.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spacer Related Acute Toxicity</title>
        <description>Assess for spacer related acute toxicity. Spacer related toxicity could be related to the procedure itself (bleeding, infection, pain), or secondary effects of spacer (erectile dysfunction, persistent pain and discomfort).</description>
        <time_frame>5 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Spacer Stability by Dimensions</title>
        <description>Determine spacer's stability during course of therapy and to ensure that it is stable enough to reliably use for high dose SABR treatments (using cone beam CTs done during each treatments to measure spacer dimensions).</description>
        <time_frame>1 month</time_frame>
        <posting_date>12/2020</posting_date>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Assessed at 1.5, 3,6, and 9 months post-treatment by direct anoscopy by the treating radiation oncologist</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Single Arm: Injectable Rectal Spacer</title>
          <description>Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent): Injectable Rectal Spacer (SpaceOAR, Duraseal or equivalent PEG based product)</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>CTCAE (4.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Anal Pain</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Anorexia</sub_title>
                <assessment>Systematic Assessment</assessment>
                <description>Loss of Appetite</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Diarrhea</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fecal Incontinence</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Flatulence</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bowel Frequency</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Bowel Urgency</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Tenesmus</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hemorrhoidal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hemorrhoids</sub_title>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Pelvic Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Perineal Pain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Proctitis</sub_title>
                <counts group_id="E1" subjects_affected="16" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rectal Hemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rectal Pain</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Rectal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Telangiectasia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <assessment>Systematic Assessment</assessment>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Paresthesia</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Weight Gain</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Bladder Spasm</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Cystitis Noninfective</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="8" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Genital Edema</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Hematuria</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Infection, Site of Spacer</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Prostatic Infection</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Prostatic Obstruction</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Dysuria</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Weak Urine Stream</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Scrotal Pain</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Frequency</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Incontinence</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Obstruction</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Retention</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Tract Pain</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Urinary Urgency</sub_title>
                <description>Non-Sexual Domain</description>
                <counts group_id="E1" subjects_affected="14" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Decreased Libido</sub_title>
                <description>Sexual Domain</description>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Ejaculation Disorder</sub_title>
                <description>Sexual Domain</description>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Erectile Dysfunction</sub_title>
                <description>Sexual Domain</description>
                <counts group_id="E1" subjects_affected="4" subjects_at_risk="44"/>
              </event>
              <event>
                <sub_title>Blood in Semen</sub_title>
                <description>Sexual Domain</description>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Rash Acneiform</sub_title>
                <counts group_id="E1" subjects_affected="10" subjects_at_risk="44"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Michael Folkert, M.D., Ph.D.</name_or_title>
      <organization>University of Texas Southwestern</organization>
      <phone>214-645-8525</phone>
      <email>Michael.Folkert@utsouthwestern.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

